Dose-Response Relationships of ACE Inhibitors and Angiotensin II Blockers by Brunner, H. R. et al.
European Heart Journal (1994) 15 (Supplement D), 123-128
Dose-response relationships of ACE inhibitors and
angiotensin II blockers
H. R. BRUNNER, J. NUSSBERGER AND B. WAEBER
Hypertension Division, University Hospital, Lausanne, Switzerland
KEY WORDS: Angiotensin I, angiotensin II, pressure response to angiotensin, plasma drug levels.
It is difficult to establish dose-response relationships for ACE inhibitors in patients with hypertension or congestive heart
failure. This has led to the widely held opinion that the effects of ACE inhibitors are hardly dose dependent. The purpose of
this short discussion is to demonstrate that this class of compounds, as well as the more recent angiotensin II receptor antag-
onists, exhibit some very clear dose-response relationships when these are evaluated in normal volunteers based on the
mechanisms for which they were designed. Characterization of these dose-response curves is important in order to use these
drugs at their optimal dose and to obtain the maximal therapeutic benefit.
Introduction
Angiotensin converting enzyme (ACE) inhibitors are now
widely used for the treatment of patients with hypertensive
disorders11"7' and with congestive heart failure18""1. Because
of their efficacy, interest in these therapeutic agents has
grown tremendously over the years; many new compounds
have been developed, and many more are being investi-
gated.
Most antihypertensive drugs were marketed at a time in
their development when their optimal therapeutic dose
was not yet established. A good example is captopril,
which, at least in some countries, was used at daily doses of
up to 450 mg, despite strong evidence that 25 mg twice or
three times a day provides close-to-maximal efficacy112-131. A
priori, it would appear that establishing the dose of an anti-
hypertensive drug should be a relatively easy and straight-
forward task. In fact, this is not so. Indeed, many difficulties
must be overcome in order to determine the optimal, i.e.
lowest, maximally effective dose of an anti-hypertensive
drug.
As pointed out by Sir George Pickering, hypertension is
a quantitative rather than a qualitative disorderl141. The
mechanisms involved in the disease, even if all are not yet
completely understood, probably also exist in normoten-
sive subjects, albeit in a quantitatively different mixture.
Accordingly, if the mechanism of action of an antihyper-
tensive agent is well understood and directed specifically to
one factor involved in blood pressure regulation, studies of
its effect in normotensive volunteers will provide useful
information to develop guidelines for the treatment of
hypertensive patients.
Several years ago, it was demonstrated that the magni-
tude of blockade achieved by ACE inhibition, the mini-
mum dose needed for maximal efficacy, and the onset and
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duration of action of the agents could be determined with
a considerable degree of accuracy by challenging nor-
motensive volunteers with repeated intravenous adminis-
trations of angiotensin (Ang) I115'. The ability of ACE to
cleave various natural and synthetic substrates has been
used to measure its activity in vitro1161. Furthermore, since
ACE inhibition causes plasma Ang II to fall and Ang I con-
centration to rise, an alternative approach to estimating the
degree of inhibition of ACE activity in vivo is to measure
plasma concentrations of Ang I and Ang II and to use
the ratio Ang II/Ang I as an estimate of in vivo ACE
inhibition1"1.
The inhibition of the pressor response to exogenous Ang
I and II has also been used in normal volunteers who were
given the angiotensin AT,, receptor antagonist losartan
orally118-"1. Losartan produced a well-tolerated, long-
lasting and clearly dose-dependent antagonism of Ang II.
These studies in normotensive subjects included single
increasing doses and repeated administration of oral
losartan.
The following will provide a short review of some
data from our laboratory which illustrate that there exist
some well defined dose-response relationships for ACE
inhibitors and AT! receptor antagonists in normal volun-
teers. There remains little doubt today that similar dose-
response relationships must exist in patients with
hypertension and even in those with congestive heart
failure, even if these are difficult to demonstrate in large
therapeutic trials.
Dose dependent effects of ACE inhibitors
It has been known for more than 20 years that the
angiotensin converting enzyme is located in the endothe-
lial cells of the cardiovascular system with a particular con-
centration in pulmonary capillaries1201. As a consequence, it
is not surprising that the bulk of the conversion of Ang I to
Ang II takes place on the surface of the endothelial cells
0195-668X/94AJD0123 + 06 $08.00/0 i 1994 The European Society of Cardiology
124 H. R. Brunner et al.
and particularly during the lung passage of the blood. There
is, however, also some converting enzyme circulating in
plasma. Even though it is well recognized that this circulat-
ing enzyme only plays a minor role in the conversion of Ang
I to Ang II, it has still been used as a marker to measure
enzyme activity in clinical situations where endothelial con-
verting enzyme activity is not easily accessible for measure-
ment. This use of plasma ACE activity as a substitute
endpoint to assess the degree of converting enzyme inhibi-
tion has introduced an important potential source of erro-
neous judgement, and it has also raised a major question,
whether plasma converting enzyme activity reflects the
activity of endothelial converting enzyme.
It has to be remembered that to measure plasma ACE
activity, plasma is incubated under standardized conditions
in vitro. To do this, various reagents are used usually with
synthetic, tripeptide substrates. The enzyme incubation
product is still measured using a variety of methods.
Depending on the conditions and the substrate that has
been utilized, very different results are obtained. Indeed, in
a given plasma obtained from a patient treated with an
ACE inhibitor, the degree of inhibition of plasma ACE
activity can be found anywhere between substantial and
nil, depending on the method used to measure it116-2'1.
Furthermore, one particular method may provide the most
realistic results for one ACE inhibiting drug, where with
another compound, one of the other methods may yield
the most accurate results. Thus, with enalapril, a method
using Hip-Gly-Gly as a substrate was found to be most
accurate, whereas in the case of benazepril, the substrate
Z-Phe-HisLeu had to be used to find the most accurate
measurement of plasma ACE activity. It is thus understood
that it is useless to report a degree of inhibition of plasma
ACE activity obtained with a certain dose of a given ACE
inhibitor without precisely describing the method used to
reach that result.
A much better way to assess the degree of converting
enzyme inhibition is to measure plasma Ang I and II and to
calculate the ratio of Ang II to Ang I. This is what we call
measurement of converting enzyme activity in vivo and has
the advantage of reflecting the physiological situation,
which also includes the action of the endothelial converting
enzyme. Undoubtedly, this method yields the most mean-
ingful results with any ACE inhibitor since it does not
introduce any major artefacts due to dissociation of the
compound from the enzyme in vitro, or due to synthetic
substitute substrates. The prerequisites, however, are
accurate methods to measure circulating Ang I and II.
Measurement of Ang I and II is needed for a precise
assessment of the efficacy of converting enzyme inhibitors
These compounds have been designed with the goal of
reducing Ang II levels. Only the measurement of Ang II
can tell by how much the renin-angiotensin system has
been inhibited. Angiotensin I, on the other hand, closely
reflects plasma renin activity and circulating levels of active
renin. Due to the suppressing effect of Ang II on renin
secretion, falling Ang II levels, in the case of converting
enzyme inhibition, induce a rise in plasma renin activity,
circulating levels of active renin and closely associated
plasma Ang I levels. These increased levels not only reflect
the degree of the compensatory rise in renin secretion but
also directly influence the circulating Ang II levels, even in
the face of converting enzyme inhibition. Indeed, a very
close correlation was found between measured Ang II
levels and the Ang I concentration divided by the concen-
tration of active drug in plasma1161 (Fig. 1).
This phenomenon becomes particularly relevant when
studying the dose-response curve of converting enzyme
inhibitors, which is known to be rather flat. It could be
shown that increasing the dose of an ACE inhibitor
resulted not only in dose-dependent converting enzyme
inhibition but also in increasing levels of circulating active
renin and Ang I levels. Though a 16-fold dose increase was
clearly reflected in more complete converting enzyme inhi-
bition, this effect was off-set by the ever-increasing Ang I
concentration'2'1. As a result, suppression of plasma
immunoreactive Ang II was not increased with the high, as
compared to the low, dose after a 10 day treatment course.
As a consequence, the dose of converting enzyme inhibitor
that should be chosen is that which provides a maximal
degree of ACE inhibition with a minimal stimulation of
renin release.
In a recent study we evaluated the dose-dependent
effects of a new ACE inhibitor, temocapril, in normal
volunteers1221. The aim of the study was to evaluate the accu-
racy of different approaches to characterizing dose-depen-
dent effects of ACE inhibitors, and particularly to compare
the inhibition of the pressor response to Ang I with plasma
ACE activity and the circulating levels of the converting
enzyme inhibitor, i.e. its potent diacid active metabolite.
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Figure I Scatter plots showing the relationship between venous
plasma angiotensin II (Ang II) concentrations and the ratio of
plasma angiotensin I (Ang I) to drug levels. Each point is the mean
of determinations in six volunteers at a given time point. (From
Juillerat el al!1*' with permission.)
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Figure 2 Correlations between plasma temocapril diacid and Ang Il/Ang I ratio (left panel) and the systolic blood pressure (SBP)
response to Ang I (right panel). (From Delacr^taz et a/.'22' with permission.)
It has been shown for the first time that the blockade of
the pressor response to Ang I with an ACE inhibitor is
closely related to the plasma level of the active compound,
i.e. the diacid metabolite (Fig. 2). In addition, the pressor
response to Ang I was also found to correlate strongly with
ACE activity in vivo, the parameter we consider to reflect
most accurately ACE inhibition.
Consequently, if inhibition of plasma ACE activity is
measured accurately, it closely predicts the reduction in
Ang II dependent blood pressure induced by an ACE
inhibitor. The correlation between plasma diacid levels and
plasma ACE activity or the pressor response to Ang I was
analysed based on a log-linear relationship. Indeed, these
parameters are expected to exhibit a relationship best
described by a sigmoidal E,™, curve. However, since high
and low extremes of drug concentrations were avoided in
this study, only the linear part of such a curve was explored
and linear regression calculated.
Dose dependent effects of angiotensin II antagonists
About 20 years ago, Ang II analogs were used as the first
specific probes to block the renin-angiotensin system in
animals and humans. It could be demonstrated for the
first time with those probes that blockade of the renin-
angiotensin system, at least in certain patients, can reduce
the blood pressure of hypertensive patients123-241. These
early compounds were later abandoned because of their
peptidic nature, which made parenteral administration
mandatory and also because of their partial agonistic Ang
II like action.
The recent reports of the synthesis and experimental
evaluations of highly active non-peptidic Ang II
antagonists has reactivated this approach to block the
renin-angiotensin system125"301. It is likely that blockade at
the receptor level provides the most specific access to inhi-
bition. Furthermore, receptor blockade leaves the possi-
bility open of specific and selective inhibition of subtypes
of Ang II receptors with different functional targeting.
Indeed, subtypes of Ang II receptors have already been
reported13'1 and it is probable that further subtypes will be
discovered in the near future.
The Ang II antagonist losartan (DuP 753 or MK 954)
has been extensively evaluated in experimental models
and found to be highly efficacious125"301. We have had the
opportunity to evaluate, for the first time, the efficacy of
this compound in blocking the Ang II induced pressor
effect in humans1'81. To this end, in an initial study, single
rising doses up to 40 mg were administered orally. In a
second investigation the same doses were given once a day
for 8 days to normal volunteers A clear dose-dependent
inhibition of the pressure response to exogenous Ang I or
II could be demonstrated with a degree of inhibition of
about 70% with the 40 mg dose. At the same time it
became evident that the effect was quite long lasting since
with the 40 mg dose, the Ang II pressure response was still
partially inhibited 24 h after drug administration1'81 (Fig. 3).
Taking into account the peak blocking effect after the
40 mg dose on the 8th day of administration, there was no
apparent cumulative effect of the drug.
Meanwhile it was demonstrated in animals that the drug
produced an active metabolite (Exp 3174) which exhibits
an at least 10-fold higher affinity to the Ang II receptor
subtype I and a longer half-life than the mother compound
losartan1321. Therefore, the purpose of the next study was
not only to investigate the effect of higher doses of losartan
on the pressure response to exogenous Ang II but also to
characterize this response as a function of the concentra-
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Days
consecutive daysFigure 3 Effects of 8  of treatment with daily
single oral doses of losanan (20 mg, 40 mg or placebo) on systolic blood pres-
sure (SBP) response to test doses of angiolensin II (Ang II) in healthy volun-
teers. 0-0 = placebo (n = 6); A-A = 20 mg (n = 5); A-A = 40 mg (n = 6)
(From Christen et a/.'18' with permission.)
tion of losartan and of its active metabolite. Six subjects
received in an open, non-randomized, cross-over fashion,
placebo and 40,80 and 120 mg losartan in a single oral dose
at one-week intervals1"1.
The parent compound was readily absorbed with a peak
reached at the first post-dose blood collection, i.e. after 1 h.
The active metabolite was eliminated much more slowly
than the parent compound and it remained detectable in
plasma for up to and rrtore than 24 h. Dose-dependent inhi-
bition of the blood pressure response to exogenous Ang
II lasting for more than 24 h was again observed. During
the 1 to 6 h post-drug period, 80 and 120 mg provided a
higher degree of inhibition than the 40 mg dose, There was
no difference between the results obtained with either 80
ox 120 mg.
The inhibition of the pressure response to the exogenous
Ang II challenge in individual subjects was then analysed
vs the respective concentrations of the active metabolite of
losartan. The Hill equation was fitted to the data of each
individual subject. To take into account the duration of the
drug effect, the integral of the percentage of inhibition over
9 h was related to the area under the curve of the active
metabolite during the same period (Fig. 4). The six individ-
ual points are plotted in three subgroups according to the
dose received. It is clearly apparent that increasing the
dose from 80 to 120 mg did not provide any enhancement
of the time integrated inhibition.
Preliminary studies in hypertensive patients using doses
between 50 and 150 mg p.o. once daily have already
demonstrated some clear antihypertensive efficacy which,
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Figure 4 Time integral of the inhibition of the pressor response to Ang II
challenge vs the area under the concentration-time curve (AUC) of the
active metabolite of losartan (Exp 3174), up to 9 h in 6 volunteers. The solid
line represents a Hill equation fit to the data. * = 40 mg; O = 80 mg;
A = 120 mg. (From Munafo et a/.''"' with permission.)
Dose-response relationships of ACE inhibitors and Ang II blockers 127
on the 5th day, was actually comparable to that of
enalapril1331. As expected, Ang II antagonism also induced
a compensatory rise in plasma renin activity, Ang I and
II'18'. Whether these elevated Ang II levels can actually
attenuate the antihypertensive effect of losartan remains to
be further investigated.
Clearly Ang II antagonism can reduce blood pressure in
hypertensive patients. Losartan, the very potent, orally
active Ang II antagonist, is now available for investiga-
tional therapeutic use. Whether this approach will turn out
to be as effective as converting enzyme inhibition in reduc-
ing blood pressure in hypertensive patients and improving
the haemodynamics of patients with congestive heart fail-
ure will be known within the next 2 to 3 years In addition,
it will be equally important to learn whether side effects
can be further reduced when changing from ACE
inhibitors to Ang II antagonists, and this is particularly
interesting in the case of ACE inhibitor induced cough or
angioneurotic oedema.
Conclusions
There remains little doubt that ACE inhibitors and Ang
II receptor antagonists exhibit distinct and well character-
ized dose-response relationships for the specific effect for
which they were designed, i.e. blockade of Ang II synthesis
or Ang II receptor interaction. Even these direct and
straight forward relationships are already attenuated and
modified by the compensatory rise in renin release induced
by the pharmacological agents.
However, when it comes to assessing the clinical effect
expected in patients with hypertension and/or congestive
heart failure, everything is much more difficult. For
instance, blood pressure reduction is not only dependent
on the induced reduction in Ang II but also on the reactive
response of the sympathetic nervous activity, on sodium
intake and renal sodium handling, on structural changes of
the vascular wall, on tissue penetration of the drug, on
blood pressure variability, etc. Considering all the variables
and possible compensatory mechanisms it is rather surpris-
ing that dose-dependent effects can sometimes be shown in
patients with cardiovascular discorders. However, distinct
dose-response relationships exist for ACE inhibitors and
Ang II receptor antagonists. They are extremely relevant
for the therapeutic use of these compounds since inade-
quate dosing can become a source for treatment failure and
side effects.
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